肺移植术后发生恶性肿瘤的研究进展

李偲涵; 唐宏涛; 徐琳; 王俊杰; 姜凯元; 严浩吉; 李昊萱; 郑翔匀; 陈婷婷; 付思怡; 田东

doi:10.3969/j.issn.1674-7445.2021.05.019

肺移植术后发生恶性肿瘤的研究进展

doi: 10.3969/j.issn.1674-7445.2021.05.019

637000 四川南充，川北医学院医学影像四川省重点实验室(李偲涵、田东)；川北医学院附属医院心肺移植研究室(李偲涵、唐宏涛、徐琳、王俊杰、姜凯元、严浩吉、李昊萱、郑翔匀、陈婷婷、付思怡、田东)；川北医学院附属医院院士(专家)工作站(田东)

基金项目:

医学影像四川省重点实验室开放课题 MIKLSP202007

四川省医学科研青年创新课题 Q18042

南充市市校合作科研专项 19SXHZ0189

川北医学院附属医院科研发展计划项目 2021ZK003

详细信息

通讯作者:
田东，男，博士，副主任医师，研究方向为肺移植基础与临床研究, E-mail: TianD_EATTS@nsmc.edu.cn

中图分类号: R617, R73
计量
- 文章访问数: 458
- HTML全文浏览量: 252
- PDF下载量: 87
- 被引次数: 0
出版历程
- 收稿日期: 2021-04-30
- 网络出版日期: 2021-09-15
- 刊出日期: 2021-09-15

Research progress on malignant tumor after lung transplantation

Medical Imaging Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong 637000, China

More Information

Corresponding author: Tian Dong, E-mail: TianD_EATTS@nsmc.edu.cn

摘要

摘要: 肺移植已经成为终末期肺病的最有效治疗手段。随着肺移植技术以及围手术期管理的不断优化，移植术后早期疗效已有明显改善，但远期预后仍不乐观。威胁受者远期生存的因素除了常见的慢性移植肺功能障碍，还包括术后恶性肿瘤。肺移植术后常见的恶性肿瘤包括非黑色素瘤皮肤癌、移植后淋巴组织增生性疾病和肺癌。实体器官移植术后绝大部分受者需要接受终身免疫抑制治疗，而肺移植受者接受的免疫抑制强度普遍高于其他器官移植受者。免疫抑制是导致受者抗肿瘤免疫监视功能受损和促进恶性肿瘤发生发展的主要因素。本文就肺移植术后最常见的几大恶性肿瘤的危险因素、预防及治疗方式做一综述，旨在为肺移植术后恶性肿瘤的综合诊治提供参考依据。
- 肺移植 /
- 恶性肿瘤 /
- 非黑色素瘤皮肤癌 /
- 移植后淋巴组织增生性疾病 /
- 肺癌 /
- 免疫抑制 /
- 危险因素 /
- 程序性细胞死亡蛋白1 /
- 西米普利单抗
Abstract: Lung transplantation has become the most effective treatment of end-stage lung diseases. Along with persistent optimization of lung transplantation technique and perioperative management, the short-term clinical efficacy after lung transplantation has been significantly improved, whereas the long-term clinical prognosis remains unoptimistic. Besides chronic lung allograft dysfunction, postoperative malignant tumors also threaten the long-term survival of the recipients. Common malignant tumors following lung transplantation include nonmelanoma skin cancer, posttransplant lymphoproliferative disease and lung cancer. After solid organ transplantation, a large majority of the recipients require lifelong immunosuppressive therapy. The intensity of immunosuppressive therapy for the lung transplant recipients is generally higher than other organ transplant recipients. Immunosuppression is the main factor which leads to the impairment of anti-tumor immune monitoring function and promotes the incidence and development of malignant tumors. In this article, the risk factors, prevention and treatment of the most common malignant tumors after lung transplantation were reviewed, aiming to provide reference for comprehensive diagnosis and treatment of malignant tumors following lung transplantation.
- Lung transplantation /
- Malignant tumor /
- Nonmelanoma skin cancer /
- Posttransplant lymphoproliferative disease /
- Lung cancer /
- Immunosuppression /
- Risk factor /
- Programmed cell death protein 1 /
- Cemiplimab

HTML全文

下载: 全尺寸图片幻灯片

参考文献(47)

[1]	Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis[J]. N Engl J Med, 1986, 314(18): 1140-1145. DOI: 10.1056/NEJM198605013141802.
[2]	CHAMBERS DC, CHERIKH WS, HARHAY MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1042-1055. DOI: 10.1016/j.healun.2019.08.001.
[3]	HAYES D JR, CHERIKH WS, CHAMBERS DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-second pediatric lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1015-1027. DOI: 10.1016/j.healun.2019.08.003.
[4]	CANGEMI M, MONTICO B, FAÈ DA, et al. Dissecting the multiplicity of immune effects of immunosuppressive drugs to better predict the risk of de novo malignancies in solid organ transplant patients[J]. Front Oncol, 2019, 9: 160. DOI: 10.3389/fonc.2019.00160.
[5]	ENGELS EA, PFEIFFER RM, FRAUMENI JF JR, et al. Spectrum of cancer risk among US solid organ transplant recipients[J]. JAMA, 2011, 306(17): 1891-1901. DOI: 10.1001/jama.2011.1592.
[6]	KATABATHINA VS, MENIAS CO, TAMMISETTI VS, et al. Malignancy after solid organ transplantation: comprehensive imaging review[J]. Radiographics, 2016, 36(5): 1390-1407. DOI: 10.1148/rg.2016150175.
[7]	ROSSI AP, KLEIN CL. Posttransplant malignancy[J]. Surg Clin North Am, 2019, 99(1): 49-64. DOI: 10.1016/j.suc.2018.09.004.
[8]	ECCHER A, GIROLAMI I, MOTTER JD, et al. Donor-transmitted cancer in kidney transplant recipients: a systematic review[J]. J Nephrol, 2020, 33(6): 1321-1332. DOI: 10.1007/s40620-020-00775-4.
[9]	MYRON KAUFFMAN H, MCBRIDE MA, CHERIKH WS, et al. Transplant tumor registry: donor related malignancies[J]. Transplantation, 2002, 74(3): 358-362. DOI: 10.1097/00007890-200208150-00011.
[10]	SCHWARZ EI, VRUGT B, HUBER LC, et al. Development of allograft cancer after lung transplantation: a case report[J]. Ann Thorac Cardiovasc Surg, 2017, 23(4): 196-199. DOI: 10.5761/atcs.cr.16-00221.
[11]	RODRIGUES D, BORRO JM, AMADO J, et al. Metachronous pulmonary neoplasms in lung transplantation-when they arise in the donor lung: a case report[J]. Transplant Proc, 2018, 50(10): 4075-4079. DOI: 10.1016/j.transproceed.2018.08.051.
[12]	QUE SKT, ZWALD FO, SCHMULTS CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors[J]. J Am Acad Dermatol, 2018, 78(2): 249-261. DOI: 10.1016/j.jaad.2017.08.058.
[13]	ELNAHAS S, OLSON MT, KANG P, et al. Factors associated with skin cancer in lung transplant recipients: a single-center experience[J]. Clin Transplant, 2019, 33(12): e13718. DOI: 10.1111/ctr.13718.
[14]	CORCHADO-COBOS R, GARCÍA-SANCHA N, GONZÁLEZ-SARMIENTO R, et al. Cutaneous squamous cell carcinoma: from biology to therapy[J]. Int J Mol Sci, 2020, 21(8): 2956. DOI: 10.3390/ijms21082956.
[15]	INMAN GJ, WANG J, NAGANO A, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature[J]. Nat Commun, 2018, 9(1): 3667. DOI: 10.1038/s41467-018-06027-1.
[16]	D'ARCY ME, PFEIFFER RM, RIVERA DR, et al. Voriconazole and the risk of keratinocyte carcinomas among lung transplant recipients in the United States[J]. JAMA Dermatol, 2020, 156(7): 772-779. DOI: 10.1001/jamadermatol.2020.1141.
[17]	ONA K, OH DH. Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A[J]. Br J Dermatol, 2015, 173(3): 751-759. DOI: 10.1111/bjd.13862.
[18]	BASU P, GOLDENBERG A, COWAN N, et al. A 4-year retrospective assessment of postoperative complications in immunosuppressed patients following Mohs micrographic surgery[J]. J Am Acad Dermatol, 2019, 80(6): 1594-1601. DOI: 10.1016/j.jaad.2018.11.032.
[19]	FRAMPTON JE, BASSET-SÉGUIN N. Vismodegib: a review in advanced basal cell carcinoma[J]. Drugs, 2018, 78(11): 1145-1156. DOI: 10.1007/s40265-018-0948-9.
[20]	BRANDT MG, MOORE CC. Nonmelanoma skin cancer[J]. Facial Plast Surg Clin North Am, 2019, 27(1): 1-13. DOI: 10.1016/j.fsc.2018.08.001.
[21]	MIGDEN MR, RISCHIN D, SCHMULTS CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma[J]. N Engl J Med, 2018, 379(4): 341-351. DOI: 10.1056/NEJMoa1805131.
[22]	ZAFFIRI L, LONG A, NEELY ML, et al. Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: analysis of ISHLT Registry[J]. J Heart Lung Transplant, 2020, 39(10): 1089-1099. DOI: 10.1016/j.healun.2020.06.010.
[23]	GREWAL HS, LANE C, HIGHLAND KB, et al. Post-transplant lymphoproliferative disorder of the bladder in a lung transplant recipient[J]. Oxf Med Case Reports, 2018(3): omx093. DOI: 10.1093/omcr/omx093.
[24]	HAJI HA, CORWIN DS, SO JY, et al. Lymphoproliferative disorder in a lung transplant recipient[J]. BMJ Case Rep, 2020, 13(3): e234532. DOI: 10.1136/bcr-2020-234532.
[25]	LEYSSENS A, DIERICKX D, VERBEKEN EK, et al. Post-transplant lymphoproliferative disease in lung transplantation: a nested case-control study[J]. Clin Transplant, 2017, 31(7). DOI: 10.1111/ctr.12983.
[26]	KUMARASINGHE G, LAVEE O, PARKER A, et al. Post-transplant lymphoproliferative disease in heart and lung transplantation: defining risk and prognostic factors[J]. J Heart Lung Transplant, 2015, 34(11): 1406-1414. DOI: 10.1016/j.healun.2015.05.021.
[27]	LONG HM, MECKIFF BJ, TAYLOR GS. The T-cell response to Epstein-Barr virus-new tricks from an old dog[J]. Front Immunol, 2019, 10: 2193. DOI: 10.3389/fimmu.2019.02193.
[28]	PROCKOP SE, VATSAYAN A. Epstein-Barr virus lymphoproliferative disease after solid organ transplantation[J]. Cytotherapy, 2017, 19(11): 1270-1283. DOI: 10.1016/j.jcyt.2017.08.010.
[29]	HUANG S, YASUDA T. Pathologically relevant mouse models for Epstein-Barr virus-associated B cell lymphoma[J]. Front Immunol, 2021, 12: 639844. DOI: 10.3389/fimmu.2021.639844.
[30]	GOTTI E, REMUZZI G. Post-transplant Kaposi's sarcoma[J]. J Am Soc Nephrol, 1997, 8(1): 130-137. DOI: 10.1681/ASN.V81130.
[31]	NAGLE SJ, RESHEF R, TSAI DE. Posttransplant lymphoproliferative disorder in solid organ and hematopoietic stem cell transplantation[J]. Clin Chest Med, 2017, 38(4): 771-783. DOI: 10.1016/j.ccm.2017.08.001.
[32]	PRAKASH K, CHANDORKAR A, SAHARIA KK. Utility of CMV-specific immune monitoring for the management of CMV in solid organ transplant recipients: a clinical update[J]. Diagnostics (Basel), 2021, 11(5): 875. DOI: 10.3390/diagnostics11050875.
[33]	KIM N, SOHN HJ, OH JH, et al. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases[J]. Int J Hematol, 2018, 107(5): 596-603. DOI: 10.1007/s12185-017-2381-3.
[34]	PÉREZ-CALLEJO D, TORRENTE M, PAREJO C, et al. Lung cancer in lung transplantation: incidence and outcome[J]. Postgrad Med J, 2018, 94(1107): 15-19. DOI: 10.1136/postgradmedj-2017-134868.
[35]	TRIPLETTE M, CROTHERS K, MAHALE P, et al. Risk of lung cancer in lung transplant recipients in the United States[J]. Am J Transplant, 2019, 19(5): 1478-1490. DOI: 10.1111/ajt.15181.
[36]	ROBBINS HY, ARCASOY SM. Malignancies following lung transplantation[J]. Clin Chest Med, 2011, 32(2): 343-355. DOI: 10.1016/j.ccm.2011.02.011.
[37]	BROWN SW, DOBELLE M, PADILLA M, et al. Idiopathic pulmonary fibrosis and lung cancer. a systematic review and Meta-analysis[J]. Ann Am Thorac Soc, 2019, 16(8): 1041-1051. DOI: 10.1513/AnnalsATS.201807-481OC.
[38]	OLLAND AB, FALCOZ PE, SANTELMO N, et al. Primary lung cancer in lung transplant recipients[J]. Ann Thorac Surg, 2014, 98(1): 362-371. DOI: 10.1016/j.athoracsur.2014.04.014.
[39]	FACCIOLI E, DELL'AMORE A, SCHIAVON M, et al. Successful lung transplantation in a patient with history of lobectomy for small cell lung cancer: a case report[J]. Transplant Proc, 2021, 53(4): 1382-1384. DOI: 10.1016/j.transproceed.2021.03.016.
[40]	VAN RAEMDONCK D, VOS R, YSERBYT J, et al. Lung cancer: a rare indication for, but frequent complication after lung transplantation[J]. J Thorac Dis, 2016, 8(Suppl 11): S915-S924. DOI: 10.21037/jtd.2016.11.05.
[41]	TIAN T, LI X, ZHANG J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy[J]. Int J Mol Sci, 2019, 20(3): 755. DOI: 10.3390/ijms20030755.
[42]	VICARY GW, ROMAN J. Targeting the mammalian target of rapamycin in lung cancer[J]. Am J Med Sci, 2016, 352(5): 507-516. DOI: 10.1016/j.amjms.2016.08.014.
[43]	ASSI HI, KAMPHORST AO, MOUKALLED NM, et al. Immune checkpoint inhibitors in advanced non-small cell lung cancer[J]. Cancer, 2018, 124(2): 248-261. DOI: 10.1002/cncr.31105.
[44]	ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 106. DOI: 10.1186/s40425-019-0585-1.
[45]	WONG G, AU E, BADVE SV, et al. Breast cancer and transplantation[J]. Am J Transplant, 2017, 17(9): 2243-2253. DOI: 10.1111/ajt.14368.
[46]	MEYER KC, FRANCOIS ML, THOMAS HK, et al. Colon cancer in lung transplant recipients with CF: increased risk and results of screening[J]. J Cyst Fibros, 2011, 10(5): 366-369. DOI: 10.1016/j.jcf.2011.05.003.
[47]	NA R, LAAKSONEN MA, GRULICH AE, et al. High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: a population-based cohort study[J]. J Am Acad Dermatol, 2016, 74(6): 1144-1152. DOI: 10.1016/j.jaad.2015.12.044.